BioCentury
ARTICLE | Clinical News

GeNeuro's GNbAC1 misses in Phase IIb for RRMS

September 22, 2017 8:16 PM UTC

GeNeuro S.A. (Euronext:GNRO) and Servier (Neuilly-sur-Seine, France) reported data from the 12-month Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis (RRMS) showing that once-monthly IV GNbAC1 missed the primary endpoint of reducing the cumulative number of gadolinium-enhancing T1 lesions on brain MRI at 6 months vs. placebo. The companies also said there was no significant difference between treatment groups on other MRI measures of neuroinflammation. GNbAC1 was well tolerated. Final 12-month data from the double-blind, European trial are expected in 1Q18. GeNeuro said the study will continue as planned to explore "potential benefits" of the compound on MRI and clinical measures, including remyelination properties.

GNbAC1 is a humanized IgG4 mAb targeting the envelope protein of human endogenous retrovirus group W member 1 (HERVW; ERVW-1). Data from a Phase IIa trial of GNbAC1 to treat Type I diabetes are expected in 3Q18...